Drugs / Anti-CD22-CAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04163575 | Feb 2020 → Jul 2021 | leukemia, lymphoma | Kecellitics Biotech Company Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD22-CAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04163575 ↗ |
| Known as | CD22CAR T-cells | “Patients will receive the CD22CAR T-cells following lymphodepleting chemotherapy.” NCT04163575 ↗ |
| Modality | Cell therapy | “CD22 Chimeric Antigen Receptor (CAR) T-cells” NCT04163575 ↗ |
| Target | CD22 | “targeting CD22” NCT04163575 ↗ |